BioAge Labs, Inc. (NASDAQ: BIOA) announced a proposed underwritten public offering of up to $75 million in common stock, with an option for underwriters to purchase an additional $11.25 million within 30 days.
The offering is intended to fund research, clinical and process development of its lead candidate BGE‑102 and its NLRP3 and APJ programs, as well as working capital, capital expenditures and general corporate purposes.
As of December 31 2025, BioAge reported $285.1 million in cash, cash equivalents and marketable securities, a balance that the company expects to sustain operations and capital needs through 2029 once the offering proceeds are added.
BGE‑102, a NLRP3 inhibitor, is the company’s flagship product. Top‑line Phase 1 data are expected in the first half of 2026, and the program is expanding into ophthalmology with a proof‑of‑concept study for diabetic macular edema slated for mid‑2026; interim Phase 1 data have already shown significant reductions in inflammatory biomarkers such as hsCRP.
The APJ program targets obesity, with both oral and injectable candidates in development; the company anticipates filing Investigational New Drug applications for these candidates by the end of 2026.
CEO Kristen Fortney highlighted the eye‑disease data, noting that the efficacy observed with injectable IL‑6 inhibitors in retinal disease validates targeting the inflammatory cascade in the eye and underscores the potential for BGE‑102 in new indications.
Following the announcement, Morgan Stanley upgraded BioAge from Underweight to Equalweight and raised its price target to $12.00, citing the promising clinical data for BGE‑102 and the strategic expansion of the pipeline.
The proposed offering represents a strategic move to secure substantial capital for advancing key clinical milestones, broaden the pipeline’s therapeutic reach, and extend the company’s cash runway well into the late‑2020s.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.